NCI-2018-01200

Phase 1, Two-Part, Multicenter, Open-Label, Multiple Dose, First-in-Human Study of DS-1062a in Subjects with Advanced Solid Tumors

This Phase 1 study evaluates a new drug called DS-1062a in subjects with advanced solid tumors. Divided into two parts, the study is multicenter, open-label, and involves multiple doses. Patients with advanced solid tumors can participate. The study aims to assess the safety, effectiveness, and recommended dosage of DS-1062a

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

open-label: Patients know which treatments are being given to them

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT03401385

Clinical Trial Site: Sinai

To see all available clinical trials click here.